Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Valion Bio (TIVC) Gross Margin (2021 - 2025)

Valion Bio has reported Gross Margin over the past 5 years, most recently at 99.32% for Q3 2025.

  • For Q3 2025, Gross Margin fell 13424.0% year-over-year to 99.32%; the TTM value through Sep 2025 reached 58.09%, down 8380.0%, while the annual FY2024 figure was 0.26%, 2415.0% down from the prior year.
  • Gross Margin for Q3 2025 was 99.32% at Valion Bio, down from 62.79% in the prior quarter.
  • Over five years, Gross Margin peaked at 71.43% in Q1 2025 and troughed at 132.78% in Q4 2024.
  • A 5-year average of 8.66% and a median of 16.36% in 2022 define the central range for Gross Margin.
  • On a YoY basis, Gross Margin climbed as much as 4136bps in 2025 and fell as far as -13424bps in 2025.
  • Year by year, Gross Margin stood at 0.51% in 2021, then soared by 2150bps to 10.54% in 2022, then tumbled by -87bps to 1.4% in 2023, then crashed by -9580bps to 132.78% in 2024, then grew by 25bps to 99.32% in 2025.
  • Business Quant data shows Gross Margin for TIVC at 99.32% in Q3 2025, 62.79% in Q2 2025, and 71.43% in Q1 2025.